Patent · US Active

Anti-ron antibodies

US8829164B2 · kind B2 · utility

0Cited by

3References

11Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

Kerry Whalen · Waltham, US
Steve Bottega · Cambridge, US
Andrea Boudrow · Peabody, US
Lyne Breault · Brookline, US
Ting Chen · Austin, US
James Gifford · Somerville, US
May Han · Brookline, US
Jinwei Jiang · Sharon, US
Lorena Lerner · Newton, US
Qing Liu · Acton, US
Kristan Meetze · Lexington, US
Sylvie Vincent · Somerville, US
Solly Weiler · Newton, US
William M. Winston, Jr. · Marlborough, US
Jeno Gyuris · Lincoln, US

Key dates

Filing date	Nov 1, 2013
Grant date	Sep 9, 2014
Priority date	—
Expiry date	Nov 1, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.